Nachrichten zur Johnson Matthey PLC Aktie

Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Todays Market

Johnson & Johnson sells products that are necessities, not just nice-to-haves.…

Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $231.73, marking a +1.05% move from the previous day.…

Top Stock Reports for Johnson & Johnson, Oracle & Netflix

Johnson & Johnson, Oracle and Netflix lead Zacks top stock reports as analysts spotlight growth drivers, cloud gains and new…

These 3 Dividend Stocks Are as Close to a Sure Thing as Investing Gets

ExxonMobil, Johnson & Johnson, and Coca-Cola are safe stocks to buy and forget.…

These 3 Dividend Stocks Are as Close to a Sure Thing as Investing Gets

ExxonMobil, Johnson & Johnson, and Coca-Cola are safe stocks to buy and forget.…

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts…

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting Data presented…

Why Is Johnson & Johnson (JNJ) Down 3.5% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings…

Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy?

Its hard to argue against its reliability.…

Johnson & Johnson reaches a milestone for one of its most exciting pipeline products

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

How Ketamine Spawned a $1.7 Billion J&J Blockbuster Drug

Spravato, the ketamine-derived nasal spray from Johnson & Johnson, was once seen as a long shot. It was difficult to…

J&J sees AI halving the time to generate drug development leads

Johnson & Johnson is using artificial intelligence to slash by half the time it takes to generate new leads for…

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Johnson & Johnson will start marketing four of its ?medications on the Trump administrations TrumpRx website on Friday, CBS News…

Jim Cramer Called Johnson & Johnson “The Best Drug Stock, or at Least the Second-Best”

Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money recently. Cramer highlighted buying the stock for…

Guggenheim raises Johnson & Johnson stock price target on Icotyde

Guggenheim raises Johnson & Johnson stock price target on Icotyde…

Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report?

Solid results werent impressive enough to move the stock price higher.…

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims…

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Johnson & Johnson: Ausblick leicht angehoben

Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Raiffeisen Bank International AG (RBI):Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI),…

Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript

…

Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers like AtaiBeckley

Johnson & Johnson (NYSE:JNJ)’s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of…

J&Js first-quarter profit beats estimates even as Stelara sales disappoint

Johnson & Johnson reported first-quarter earnings that beat Wall Street expectations on Tuesday and raised its full-year forecast, as strong…

Johnson & Johnson beats quarterly revenue estimates, maintains full-year outlook

Johnson & Johnson (NYSE:JNJ) reported first-quarter results on Tuesday that beat Wall Street expectations for revenue, driven by solid growth…

1 Stock to Buy, 1 Stock to Sell This Week: Netflix, Johnson & Johnson

Market Analysis by covering: SPDR® S&P 500® ETF Trust, Invesco QQQ Trust, Johnson & Johnson, Netflix Inc. Read s…

HURA: 2025 Financial Results

By John Vandermosten, CFANASDAQ: HURAREAD THE FULL HURA RESEARCH REPORTOperational and Financial ResultsOn April 1st, 2026, TuHURA Biosciences, Inc. (NASDAQ:…

Gear Up for Johnson & Johnson (JNJ) Q1 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Streets top-and-bottom-line estimates for Johnson & Johnson (JNJ), review projections for some of its key metrics to gain…

Johnson & Johnson Aktie: Kaufchance! Beginnt jetzt die nächste Wachstumsphase?

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Goldman Sachs:Goldman Sachs bestätige vor den Ergebnissen zum ersten Quartal das "buy"-Votum…

Johnson & Johnson Aktie: Höheres Kursziel trotz Branchenunsicherheit

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Citi:Die Analysten von Citi haben das Kursziel für die Aktie von Johnson…

Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know

Johnson & Johnson (JNJ) closed at $241.3 in the latest trading session, marking a +1.21% move from the prior day.…

Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030

…

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key…

This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…

Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing

Johnson & Johnson (JNJ) closed the most recent trading day at $239.93, moving +1.98% from the previous trading session.…

The Zacks Analyst Blog JPMorgan, Johnson & Johnson, Applied Materials and Value Line

JPMorgan, Johnson & Johnson and Applied Materials stand out in new research reports, highlighting strong business momentum despite industry and…

JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU

Johnson & Johnson seeks EMA nod to expand Tecvayli monotherapy use in earlier-line RRMM, backed by phase III MajesTEC-9 data…

Johnson & Johnson Aktie: Medizintechnik-Sektor weiter in starker Verfassung

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Citigroup:Citi habe das Kursziel für die Aktie von Johnson & Johnson (J&J)…

Scherbaums Börse: Die Stärke von Johnson & Johnson

Donald Trump zwingt Pharmakonzerne zu Preisnachlässen. Doch ausgerechnet Johnson & Johnson liefert überraschend starke Zahlen. Anleger stellen sich nun eine…

Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $239.63, denoting a -2.31% move from…

Johnson & Johnson launches website for direct-to-consumer sales

Johnson & Johnson has launched a website to sell some of its drugs directly to U.S. patients who either dont…

Johnson & Johnson launches website for direct-to-consumer sales

Johnson & Johnson launches website for direct-to-consumer sales…

Johnson & Johnson Aktie: BofA sieht mehr Umsatzpotenzial - Fokus auf Tecvayli und Inlexzo

Charlotte (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von BofA Securities:Jason Gerberry, Analyst von BofA Securities, stuft die Aktie von Johnson &…

Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors

Johnson & Johnson (JNJ) closed the most recent trading day at $248.43, moving +2.04% from the previous trading session.…

Bayer verklagt Johnson & Johnson – Aktie fällt und fällt

Der DAX-Konzern Bayer will sich in den Vereinigten Staaten juristisch gegen Johnson & Johnson wehren. Der Hintergrund für die Klage…

Bayer verklagt Johnson & Johnson – Aktie fällt und fällt

Der DAX-Konzern Bayer will sich in den Vereinigten Staaten juristisch gegen Johnson & Johnson wehren. Der Hintergrund für die Klage…

Bayer verklagt Johnson & Johnson wegen irreführender Werbung

Von Nicholas G. Miller DOW JONES--Die Bayer AG verklagt Johnson Johnson (JJ) und deren Sparte Janssen Biotech wegen…

Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs

JNJs diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with…

Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio

Its about striking that perfect balance between chasing growth and protecting what you already have.…

Honeywell Considers Walking Away From Johnson Matthey Catalyst Deal

Honeywell International Inc. is considering walking away from its acquisition of Johnson Matthey Plc’s Catalyst Technologies business, people familiar with…